Gateway Investment Advisers LLC Raises Position in Illumina, Inc. (NASDAQ:ILMN)

Gateway Investment Advisers LLC boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 8.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,463 shares of the life sciences company's stock after buying an additional 2,196 shares during the period. Gateway Investment Advisers LLC's holdings in Illumina were worth $3,937,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Millennium Management LLC grew its position in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company's stock worth $155,067,000 after acquiring an additional 1,118,747 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Illumina in the 2nd quarter worth about $77,628,000. Massachusetts Financial Services Co. MA increased its position in shares of Illumina by 148.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company's stock valued at $137,735,000 after purchasing an additional 631,294 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after buying an additional 625,245 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new stake in Illumina in the 3rd quarter worth approximately $57,380,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 0.5 %

Shares of NASDAQ:ILMN traded down $0.70 during midday trading on Friday, reaching $136.67. The company's stock had a trading volume of 1,247,185 shares, compared to its average volume of 1,836,016. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The firm has a market capitalization of $21.68 billion, a P/E ratio of -13.72 and a beta of 1.11. The firm has a 50 day moving average of $139.60 and a 200-day moving average of $133.37. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the firm earned $0.33 earnings per share. The business's revenue for the quarter was down 3.5% on a year-over-year basis. On average, research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Royal Bank of Canada lifted their target price on shares of Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Piper Sandler cut their price target on shares of Illumina from $195.00 to $185.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. JPMorgan Chase & Co. lifted their price objective on Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Finally, Robert W. Baird increased their target price on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.